Palvella Therapeutics, Inc. (PVLA) Cash & Equivalents (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Cash & Equivalents for 12 consecutive years, with $14.2 million as the latest value for Q3 2024.
- On a quarterly basis, Cash & Equivalents fell 68.29% to $14.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $14.2 million, a 68.29% decrease, with the full-year FY2023 number at $7.4 million, down 80.98% from a year prior.
- Cash & Equivalents was $14.2 million for Q3 2024 at Palvella Therapeutics, down from $14.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $119.1 million in Q2 2021 to a low of $6.2 million in Q1 2024.
- A 5-year average of $51.2 million and a median of $47.4 million in 2020 define the central range for Cash & Equivalents.
- Peak YoY movement for Cash & Equivalents: soared 168.83% in 2021, then plummeted 87.09% in 2024.
- Palvella Therapeutics' Cash & Equivalents stood at $70.4 million in 2020, then surged by 67.19% to $117.8 million in 2021, then tumbled by 67.19% to $38.6 million in 2022, then plummeted by 80.98% to $7.4 million in 2023, then soared by 93.29% to $14.2 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Cash & Equivalents are $14.2 million (Q3 2024), $14.5 million (Q2 2024), and $6.2 million (Q1 2024).